In conclusion, a picture emerges in which not only NEAT1 is unable to increase its levels in a sufficient manner to counteract CDK5R1 increase in AD brains, but also, it loses the ability to positively regulate miR-15/107, validated negative regulators of CDK5R1. In this way, converging pathological mechanisms based on a failure of lncRNA NEAT1 and miR-15/107 homeostatic role towards CDK5R1 expression could result in CDK5R1 upregulation. This evidence concerns the gene NEAT1 and Alzheimer disease.